Literature DB >> 18090928

Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients.

Nadezhda V Koshkina1, Eugenie S Kleinerman, Guojun Li, Chong C Zhao, Qingyi Wei, Erich M Sturgis.   

Abstract

Defective apoptosis signaling by the Fas pathway has carcinogenic implications. We analyzed 123 pediatric patients with osteosarcoma for Fas single nucleotide polymorphisms: 2 of the promoter region (-1377 G>A and -670 A>G) and 2 of the coding region (exon 3 18272 A>G and exon 7 22628 C>T). As a comparison group, we used 510 adults without a history of cancer. We found an increased risk of osteosarcoma associated with the heterozygous genotype Fas exon 3 AG (genotype frequency 19.5% in cases vs. 12.0% in controls, P=0.028; adjusted odds ratio=1.6, 95% confidence interval=0.9-2.7], and this association was more pronounced in non-Hispanic whites (20.6% in cases vs. 10.1% in controls, P=0.014; adjusted odds ratio=2.3, 95% confidence interval=1.2-4.6). Additionally, the frequency of the variant allele (exon 3 G) was significantly higher in cases than in controls for both the entire group and non-Hispanic whites (P=0.046 and P=0.030, respectively). We found no significant association between osteosarcoma risk and the other Fas polymorphisms. This study suggests an association between the Fas exon 3 A>G polymorphism and osteosarcoma risk; however, further study is needed with pediatric controls and a larger sample size.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090928     DOI: 10.1097/MPH.0b013e3181581506

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  22 in total

1.  Genetic variation at chromosome 8q24 in osteosarcoma cases and controls.

Authors:  Lisa Mirabello; Sonja I Berndt; Guillermo F Seratti; Laurie Burdett; Meredith Yeager; Salma Chowdhury; Kedest Teshome; Arinze Uzoka; Chester Douglass; Richard B Hayes; Robert N Hoover; Sharon A Savage
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

2.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

3.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

Review 4.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

5.  Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population.

Authors:  Zhen Wang; Peng Wen; Xiaojun Luo; Xiaomin Fang; Qingfeng Wang; Feng Ma; Jinhan Lv
Journal:  Tumour Biol       Date:  2013-12-06

6.  Telomere length and variation in telomere biology genes in individuals with osteosarcoma.

Authors:  Lisa Mirabello; Elliott G Richards; Linh M Duong; Kai Yu; Zhaoming Wang; Richard Cawthon; Sonja I Berndt; Laurie Burdett; Salma Chowdhury; Kedest Teshome; Chester Douglass; Sharon A Savage
Journal:  Int J Mol Epidemiol Genet       Date:  2010-11-23

7.  Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk.

Authors:  Yu He; XinJun Liang; ChunQing Meng; ZengWu Shao; Yong Gao; Qiang Wu; JianXiang Liu; Hong Wang; ShuHua Yang
Journal:  Int Orthop       Date:  2014-05-31       Impact factor: 3.075

8.  miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Authors:  Yuanzheng Yang; Gangxiong Huang; Zhichao Zhou; Jason G Fewell; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2017-10-27       Impact factor: 6.261

Review 9.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

10.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.